Sen. Alexander Details His Plan To Fix Surprise Medical Bills
19 Jun 2019 21:50:24 Z
A legislative package from Sens. Lamar Alexander (R-Tenn.) and Patty Murray (D-Wash.) would handle surprise medical bills by having insurers pay them the “median in-network rate,” meaning the rate would be similar to what the plan charges other doctors in the area for the same procedure.
Senators Agree Surprise Medical Bills Must Go. But How?
The Senate Health, Education, Labor and Pensions Committee is scheduled next week to mark up a massive legislative package on curbing health costs, but some of the details remain unresolved, including what formula to use to pay doctors and hospitals involved in surprise medical bills.
Miracle Machine Makes Heroic Rescues — And Leaves Patients In Limbo
The use of ECMO, the most aggressive form of life support in modern medicine, has skyrocketed — but along with miraculous rescues, it can leave patients in limbo, kept alive with machines but with no prospect of survival outside the ICU.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
In Combating Surprise Bills, Lawmakers Miss Sky-High Air Ambulance Costs
The median cost of an air ambulance bill is more than $36,000 and seldom covered by insurance, sparking many consumer complaints. Yet none of the proposals introduced or circulating in Congress to fix surprise medical bills address these services.
Trump Administration Rule Would Undo Health Care Protections For LGBTQ Patients
Supporters of the rule say it would strengthen health care professionals’ freedom of conscience, but opponents say it “empowers bad actors to be bad actors.”
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.
FAQ: How Does New Trump Fetal Tissue Policy Impact Medical Research?
The scientific use of tissue from aborted fetuses has frequently been a hot point of contention between anti-abortion forces and researchers. It heats up again as federal officials announced this week they were ending NIH research using the tissue.
KHN’s ‘What The Health?’: Fetal Tissue Research Is Latest Flashpoint In Abortion Debate
Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Paige Winfield Cunningham of The Washington Post join KHN’s Julie Rovner to discuss the Trump administration’s efforts to curtail federally funded research using fetal tissue, the backlash from former Vice President Joe Biden’s support for the anti-abortion Hyde Amendment and how health policy intersects with both trade and immigration policy.